ArticleVaccine: X2026
Barriers and facilitators of respiratory syncytial virus (RSV) vaccine confidence among a community-based sample of predominantly Latino older adults in San Francisco.
Article in Vaccine: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Respiratory Syncytial Virus (RSV) Vaccine Acceptance Among the Elderly in Al-Qassim Region, Saudi Arabia.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background: The new and effective RSV vaccine can reduce morbidity from RSV among older adults, yet uptake is below goal and there are differences across race/ethnicity groups. Thus, we sought to identify barriers and facilitators to RSV vaccine uptake among Latino older adults and evaluate the potential of multi-generational vaccine recommendation. Methods: In this cross-sectional study, we administered 403 surveys (200 among adults 60+) to a convenience sample of adults at Latino-focused community-based organizations. Surveys assessed barriers and facilitators of RSV vaccination using the Behavioral and Social Drivers (BeSD) framework. We assessed sociodemographic variables and the odds of being motivated to get or recommend the RSV vaccine with a logistic regression, adjusting by age, sex, and race. Results: Majority of participants were Latino (94.5%) and born outside of the U.S. (87%). Among adults 60+, 3% received the RSV vaccine, whereas 46% received the zoster vaccine and 96% received a COVID vaccine. Prior to survey completion, 60% had never heard of the RSV virus. Once made aware of RSV and vaccine eligibility, 67% were motivated to get vaccinated and 68% felt the vaccine was very important. Older adults' motivation to get the RSV vaccine was linked to confidence in vaccine safety (aOR: 8.9, 95%CI: 2.9-26.9), trust in health workers (aOR: 5, 95%CI: 1.7-14.7), and social norms- family and friends want them to get vaccinated (aOR: 5.2, 95%CI: 2.5-10/8). Among people 18-59 years, 76% discuss health matters with their older family members and 69% would recommend the RSV vaccine. Conclusion: Though uptake was only 3% at baseline, motivation to get vaccinated was high after hearing about RSV vaccine eligibility. Strategies to increase uptake should include education from trusted sources including health care providers, family members and friends about vaccine eligibility and access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.